(100.24.118.144)
Users online: 1647    [ij] [ij] [ij] 
Email id
 

RESEARCH JOURNAL OF PHARMACY AND TECHNOLOGY
Year : 2020, Volume : 13, Issue : 12
First page : ( 5876) Last page : ( 5880)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.01024.0

Comparative pharmacokinetic study of risedronate 35 mg healthy male subjects under fed conditions

Colaco Socorrina1*, Ramesh N.2, Shabaraya Ramakrishna2

1department of Pharmacology, GITAM Institute of Medical Sciences and Research, GITAM, Rushikonda, Visakhapatnam-530045Andhra PradeshIndia.

2Department of Pharmaceutics, Srinivas College of Pharmacy, Farengipete Post, Mangalore-574143, Karnataka, India.

*Corresponding Author E-mail: drsc77@gmail.com

Online published on 15 February, 2021.

Abstract

The main objective of this research work was to evaluate the pharmacokinetics and the comparative oral bioavailability of newly developed Risedronate 35 mg test 1, test 2 and reference drug in 9 healthy male subjects under fed conditions. Single dose of either of the investigational products was administered orally in each period. A washout period of 7 days was provided between the following dosing days. The plasma concentrations of Risedronate were analyzed using a suitably validated LCMS/MS assay method. A calibration curve extending over the range 0.1974 ng/mL to 29.6121ng/mL with a LLOQ of 0.1974 ng/mL was used in subject sample analysis of Risedronate. Pharmacokinetic parameters Cmax, Tmax, AUC t, AUC mf, K el, T half were calculated for Risedronate. These pharmacokinetic parameters were calculated using the non-compartmental model of pharmacokinetic software. The two one-sided confidence intervals were calculated for the un-transformed and ln-transformed ratios of the pharmacokinetic parameters, Cmax, AUCt and AUCmf, for Bioequivalence of newly developed drug vs. Reference drug was equivalent in terms of rate of amount and absorption for Risedronate.

Top

Keywords

Risedronate, Pharmacokinetics, Oral Bioavailability, Fed condition, LCMS/MS.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
596,115,394 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.